Shivaani Kummar

No bio available.

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Moderna Inc
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    AstraZeneca LP
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Immunitas Therapeutics, Inc.
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Transcenta Therapeutics, Inc.
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Bristol Myers Squibb
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Adanate, Inc.
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    23andMe Inc.
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Gilead Sciences Inc.
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    DOT Therapeutics-1 Inc.
    Date added:
    09/24/2024
    Date updated:
    09/24/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    PMV Pharmaceuticals, Inc.
    Date added:
    09/24/2024
    Date updated:
    09/24/2024

Pages

Return to 4th Binaytara Precision Oncology Summit: Current Standards and Emerging Therapies